339 related articles for article (PubMed ID: 16007095)
1. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
Guan Y; Hao C; Cha DR; Rao R; Lu W; Kohan DE; Magnuson MA; Redha R; Zhang Y; Breyer MD
Nat Med; 2005 Aug; 11(8):861-6. PubMed ID: 16007095
[TBL] [Abstract][Full Text] [Related]
2. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats.
Chen L; Yang B; McNulty JA; Clifton LG; Binz JG; Grimes AM; Strum JC; Harrington WW; Chen Z; Balon TW; Stimpson SA; Brown KK
J Pharmacol Exp Ther; 2005 Feb; 312(2):718-25. PubMed ID: 15475592
[TBL] [Abstract][Full Text] [Related]
3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
4. PPARγ-induced stimulation of amiloride-sensitive sodium current in renal collecting duct principal cells is serum and insulin dependent.
Chraïbi A; Renauld S
Cell Physiol Biochem; 2014; 33(3):581-93. PubMed ID: 24603133
[TBL] [Abstract][Full Text] [Related]
5. PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules.
Fu Y; Gerasimova M; Batz F; Kuczkowski A; Alam Y; Sanders PW; Ronzaud C; Hummler E; Vallon V
Nephron; 2015; 129(1):68-74. PubMed ID: 25531136
[TBL] [Abstract][Full Text] [Related]
6. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
7. TZDs and diabetes: testing the waters.
Semenkovich CF
Nat Med; 2005 Aug; 11(8):822-4. PubMed ID: 16079871
[No Abstract] [Full Text] [Related]
8. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling.
Endo Y; Suzuki M; Yamada H; Horita S; Kunimi M; Yamazaki O; Shirai A; Nakamura M; Iso-O N; Li Y; Hara M; Tsukamoto K; Moriyama N; Kudo A; Kawakami H; Yamauchi T; Kubota N; Kadowaki T; Kume H; Enomoto Y; Homma Y; Seki G; Fujita T
Cell Metab; 2011 May; 13(5):550-61. PubMed ID: 21531337
[TBL] [Abstract][Full Text] [Related]
9. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
Zhang H; Zhang A; Kohan DE; Nelson RD; Gonzalez FJ; Yang T
Proc Natl Acad Sci U S A; 2005 Jun; 102(26):9406-11. PubMed ID: 15956187
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
Pavlov TS; Levchenko V; Karpushev AV; Vandewalle A; Staruschenko A
Mol Pharmacol; 2009 Dec; 76(6):1333-40. PubMed ID: 19752200
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
Buckingham RE; Hanna A
Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
[TBL] [Abstract][Full Text] [Related]
14. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
15. Hyperaldosteronemia and activation of the epithelial sodium channel are not required for sodium retention in puromycin-induced nephrosis.
Lourdel S; Loffing J; Favre G; Paulais M; Nissant A; Fakitsas P; Créminon C; Féraille E; Verrey F; Teulon J; Doucet A; Deschênes G
J Am Soc Nephrol; 2005 Dec; 16(12):3642-50. PubMed ID: 16267158
[TBL] [Abstract][Full Text] [Related]
16. Fluid retention mediated by renal PPARgamma.
Staels B
Cell Metab; 2005 Aug; 2(2):77-8. PubMed ID: 16098822
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.
Borsting E; Cheng VP; Glass CK; Vallon V; Cunard R
Am J Physiol Renal Physiol; 2012 Mar; 302(5):F540-51. PubMed ID: 22169011
[TBL] [Abstract][Full Text] [Related]
18. PPARgamma agonists, modulation of ion transporters, and fluid retention.
Nofziger C; Blazer-Yost BL
J Am Soc Nephrol; 2009 Dec; 20(12):2481-3. PubMed ID: 19820124
[No Abstract] [Full Text] [Related]
19. Chronic lithium treatment inhibits amiloride-sensitive sodium transport in the rat distal nephron.
Thomsen K; Bak M; Shirley DG
J Pharmacol Exp Ther; 1999 Apr; 289(1):443-7. PubMed ID: 10087036
[TBL] [Abstract][Full Text] [Related]
20. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease.
Mall MA
Exp Physiol; 2009 Feb; 94(2):171-4. PubMed ID: 19060118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
